Qualigen Therapeutics (NASDAQ:AIXC) Releases Quarterly Earnings Results

Qualigen Therapeutics (NASDAQ:AIXC) posted its quarterly earnings results on Monday. The company reported ($3.76) earnings per share (EPS) for the quarter, FiscalAI reports.

Qualigen Therapeutics Stock Up 8.7%

AIXC stock opened at $1.25 on Wednesday. Qualigen Therapeutics has a one year low of $0.92 and a one year high of $8.81. The firm’s 50-day moving average price is $1.31. The stock has a market capitalization of $6.45 million, a price-to-earnings ratio of -0.17 and a beta of 0.38.

Analysts Set New Price Targets

Separately, Weiss Ratings assumed coverage on Qualigen Therapeutics in a report on Monday, January 26th. They issued a “sell (e+)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.